Inovio Pharmaceuticals, Inc. (INO)Healthcare | Biotechnology | Plymouth Meeting, United States | NasdaqCM
1.19 USD
+0.03
(2.586%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 1.21 +0.02 (1.655%) ⇧ (April 17, 2026, 7:59 p.m. EDT) Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 1:15 a.m. EDT
This is a 'sell on any strength' diagnosis. Fundamentally, INO is bleeding value with -100% revenue growth and massive debt-to-equity (38x) despite a 1.4 current ratio; the stock has lost ~88% value year-over-year. While the stock is technically oversold and showing signs of a trend reversal (news mentions 'PDUFA inflection' and 'trend reversal'), the sheer dilution from recent $17.5M stock offerings and the heavy put activity suggest the $1.19 level is fragile. The massive 5/08 volatility play suggests a binary event is coming, but without the product data (PDUFA date) providing a definitive 'yes,' the probability of collapse outweighs the probability of a recovery. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.113870 |
| AutoETS | 0.120506 |
| AutoARIMA | 0.120509 |
| AutoTheta | 0.171316 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 19% |
| H-stat | 9.63 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 2.81 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 38.877 |
| Revenue per Share | 0.001 |
| Market Cap | 97,094,424 |
| Forward P/E | -2.05 |
| Beta | 1.70 |
| Website | https://www.inovio.com |
As of April 19, 2026, 1:15 a.m. EDT: Options flow reveals a distinct contradiction. Near-term expiration (4/24 to 5/01) shows heavy put volume at strikes below the current price ($1.0 ATM), suggesting a defensive hedge against further downside. However, a massive 'straddle' was placed on the 5/08 expiration across the board (880 Call Vol + 550 Put Vol), indicating an expectation of high volatility rather than a specific directional bias. Single massive flow on the 1.5 strike call for 5/08 dominates the volume profile, slightly tipping the sentiment toward a bounce or gap-up in May. Lower-dated OTM calls (3.0 strike) show significant Open Interest, implying a speculative long-term upside thesis despite the current price crush.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.33146065 |
| Address1 | 660 West Germantown Pike |
| Address2 | Suite 110 |
| All Time High | 2,352.0 |
| All Time Low | 1.03 |
| Ask | 1.35 |
| Ask Size | 1 |
| Average Analyst Rating | 2.0 - Buy |
| Average Daily Volume10 Day | 3,133,080 |
| Average Daily Volume3 Month | 1,566,770 |
| Average Volume | 1,566,770 |
| Average Volume10Days | 3,133,080 |
| Beta | 1.703 |
| Bid | 1.01 |
| Bid Size | 1 |
| Book Value | 0.349 |
| City | Plymouth Meeting |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.19 |
| Current Ratio | 1.4 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.2 |
| Day Low | 1.16 |
| Debt To Equity | 38.877 |
| Display Name | Inovio Pharmaceuticals |
| Earnings Call Timestamp End | 1,773,347,400 |
| Earnings Call Timestamp Start | 1,773,347,400 |
| Earnings Timestamp | 1,773,345,600 |
| Earnings Timestamp End | 1,778,702,400 |
| Earnings Timestamp Start | 1,778,702,400 |
| Ebitda | -85,404,192 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.387 |
| Enterprise To Revenue | 506.172 |
| Enterprise Value | 33,074,790 |
| Eps Current Year | -1.0425 |
| Eps Forward | -0.58 |
| Eps Trailing Twelve Months | -1.81 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.5568 |
| Fifty Day Average Change | -0.36679995 |
| Fifty Day Average Change Percent | -0.23561148 |
| Fifty Two Week Change Percent | -33.146065 |
| Fifty Two Week High | 2.98 |
| Fifty Two Week High Change | -1.79 |
| Fifty Two Week High Change Percent | -0.6006711 |
| Fifty Two Week Low | 1.03 |
| Fifty Two Week Low Change | 0.16000009 |
| Fifty Two Week Low Change Percent | 0.1553399 |
| Fifty Two Week Range | 1.03 - 2.98 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 913,127,400,000 |
| Float Shares | 68,803,152 |
| Forward Eps | -0.58 |
| Forward P E | -2.0517242 |
| Free Cashflow | -38,681,548 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 112 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -54,141,532 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0042 |
| Held Percent Institutions | 0.42139998 |
| Implied Shares Outstanding | 81,591,956 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://ir.inovio.com/ |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,706,140,800 |
| Last Split Factor | 1:12 |
| Long Business Summary | Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania. |
| Long Name | Inovio Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 97,094,424 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_28922 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -84,945,904 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 97,502,387 |
| Number Of Analyst Opinions | 6 |
| Open | 1.18 |
| Operating Cashflow | -88,629,432 |
| Operating Margins | -1,328.7131 |
| Payout Ratio | 0.0 |
| Phone | 267 440 4200 |
| Post Market Change | 0.019699931 |
| Post Market Change Percent | 1.6554563 |
| Post Market Price | 1.2097 |
| Post Market Time | 1,776,470,392 |
| Previous Close | 1.16 |
| Price Eps Current Year | -1.1414869 |
| Price Hint | 4 |
| Price To Book | 3.409742 |
| Price To Sales Trailing12 Months | 1,485.9193 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.34 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.0 |
| Region | US |
| Regular Market Change | 0.0300001 |
| Regular Market Change Percent | 2.58621 |
| Regular Market Day High | 1.2 |
| Regular Market Day Low | 1.16 |
| Regular Market Day Range | 1.16 - 1.2 |
| Regular Market Open | 1.18 |
| Regular Market Previous Close | 1.16 |
| Regular Market Price | 1.19 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 2,031,271 |
| Return On Assets | -0.57879 |
| Return On Equity | -1.8346801 |
| Revenue Growth | -1.0 |
| Revenue Per Share | 0.001 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 81,591,956 |
| Shares Percent Shares Out | 0.14310001 |
| Shares Short | 9,884,839 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 10,960,650 |
| Short Name | Inovio Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.1668 |
| Short Ratio | 14.51 |
| Source Interval | 15 |
| State | PA |
| Symbol | INO |
| Target High Price | 13.0 |
| Target Low Price | 1.8 |
| Target Mean Price | 6.96667 |
| Target Median Price | 6.0 |
| Total Cash | 58,512,464 |
| Total Cash Per Share | 0.847 |
| Total Debt | 9,367,826 |
| Total Revenue | 65,343 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.81 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.87935 |
| Two Hundred Day Average Change | -0.6893499 |
| Two Hundred Day Average Change Percent | -0.3668023 |
| Type Disp | Equity |
| Volume | 2,031,271 |
| Website | https://www.inovio.com |
| Zip | 19,462 |